The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://livebackpage.com/story6181755/retatrutide-vs-tirzepatide-a-comparative-analysis